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Psoriasis is a chronic in¯ammatory skin disease in
which epidermal hyperplasia results from the release
of cytokines by in®ltrating type 1 T cells. Up-
regulation of endogenous interleukin-10 controls
type 1 skin responses in animal models; however,
interleukin-10 production is low in psoriatic lesions.
Consistent with an important role of interleukin-10
in psoriasis, we and colleagues have recently demon-
strated clinical ef®cacy of subcutaneous administra-
tion of recombinant interleukin-10 to affected
patients. Here, we studied the effects of interleukin-
10 on disease-related in¯ammatory pathways.
Patients were treated with recombinant interleukin-
10 over 6 wk in an open-label phase II clinical trial.
Tissue was obtained before and after therapy and
examined by histology/immunohistochemistry, in
situ hybridization, and quantitative real-time reverse
transcription±polymerase chain reaction. Ten of 14
patients showed a marked reduction of the clinical
disease activity. The clinical response was associated
with a signi®cant decrease of cutaneous T cell in®l-
tration and the lesional expression of type 1 cyto-
kines interferon-g and tumor necrosis factor-a.
Interleukin-10 inhibited the epidermal interleukin-8
pathway by downregulating the expression of inter-
leukin-8, its receptor CXCR2, and its inducer inter-
leukin-17, and partially reversed the aberrant
keratinocyte maturation de®ning psoriatic epidermal
pathology. Remarkably, there was evidence that
genetic factors are involved in the response to inter-
leukin-10 as individual variations in the downregula-
tion of tumor necrosis factor-a were related to the
presence of polymorphisms in the tumor necrosis
factor-a promoter. These data suggest that excessive
production of type 1 cytokines in human skin disease
can be counter-regulated by the administration of
recombinant interleukin-10. Genotypic analysis may
help to identify patients that will preferentially
respond to interleukin-10 therapy. Key words: immu-
notherapy/in¯ammation/skin/Th1/Th2. J Invest Dermatol
116:319±329, 2001
P
soriatic skin lesions are characterized by in¯ammation,
with T cells and neutrophils in®ltrating both the
dermis and epidermis, and excessive scaling related to
epidermal hyperproliferation and aberrant keratino-
cyte differentiation (Camp, 1998). More recently, the
in¯ammatory process was found to be associated with characteristic
changes in the cutaneous cytokine pro®le. The presence of high
levels of interleukin (IL)-2, interferon (IFN)-g, and tumor necrosis
factor (TNF)-a compared with low levels of IL-4 and IL-5 in
psoriatic lesions is believed to re¯ect a preferential type 1 immune
response (Uyemura et al, 1993; Schlaak et al, 1994). In¯ammatory
pathways similar to those observed in other epithelial-related
chronic in¯ammatory type 1 disorders such as Crohn's disease
(Parronchi et al, 1997) may therefore be relevant in the
pathogenesis of psoriasis.
Several ®ndings indicate that a cutaneous overexpression of type
1 cytokines in fact contributes to disease manifestation. The
production of TNF-a and IFN-g in psoriatic lesions correlates with
the expression of endothelial leukocyte adhesion molecule and
vascular cell adhesion molecule-1 on dermal endothelial cells
(Uyemura et al, 1993), an important component in the regulation
of T cell and neutrophil traf®c into the skin. TNF-a and IFN-g
synergistically activate nonprofessional antigen-presenting cell
(APC) functions in keratinocytes that have been suggested to play
a part in the initiation of psoriatic skin in¯ammation (Nickoloff et al,
1993). Type 1 cytokines may also promote excessive keratinocyte
proliferation because the stimulation of keratinocyte growth by
supernatants derived from lesional T cells was found to depend on
the presence of IFN-g (Prinz et al, 1994; Bata-Csorgo et al, 1995).
In addition, type 1 cytokines are able to activate other
proin¯ammatory cytokine pathways. For example, IFN-g and
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TNF-a induce the production of IL-8 in keratinocytes (Barker et al,
1990), which is overexpressed in psoriatic epidermis, and is
regarded as a key factor in the recruitment of leukocytes and the
development of epidermal dysfunction (Schmid et al, 1993;
Kemeny et al, 1995; Bruch-Gerharz et al, 1996). The concept of
a pathogenic role for activated T cells and cytokines in psoriasis is
further supported by the bene®cial effects of T cell-directed
therapeutic agents such as cyclosporine A, fumaric acid esters, anti-
CD4 antibodies, and the lymphocyte-selective toxin DAB389 IL-2
(Nicolas et al, 1991; Gottlieb et al, 1995; De Jong et al, 1996).
The mechanisms that drive the activation of the type 1 pathway
in psoriasis are incompletely understood. APC may be involved, as
dendritic cells derived from lesional skin propagate the develop-
ment of T cells that produce high levels of IL-2 and IFN-g, but
little or no IL-4 and IL-10 (Nestle et al, 1994). IL-10 is a potent
inhibitor of APC-dependent T cell proliferation and type 1
cytokine production (reviewed by De Vries, 1995). These activities
of IL-10 are also essential in the control of in¯ammatory skin
responses. IL-10 converts epidermal Langerhans cells from potent
inducers of primary immune responses to speci®cally tolerizing cells
(Enk et al, 1993). It also abrogates the effect of dendritic cells from
psoriatic lesions on type 1 cytokine synthesis in T cells (Mitra et al,
1995). In support of these in vitro ®ndings exogenous application of
IL-10 has been shown to suppress cutaneous delayed-type
hypersensitivity reactions (Ferguson et al, 1994; Li et al, 1994). In
normal skin, upregulation of endogenous IL-10 was shown to
restore cutaneous immune homeostasis during in¯ammation
(Ferguson et al, 1994; Berg et al, 1995); however, expression of
IL-10 is weak or absent in psoriatic skin compared with other
in¯ammatory dermatoses (Nickoloff et al, 1994; Asadullah et al,
1998). There is now increasing evidence that upregulation of
endogenous IL-10 is part of the response of psoriasis to
conventional therapies such as fumaric ester derivatives (De Jong
et al, 1996), topical vitamin D3 analogs (Kang et al, 1998), and
ultraviolet (UV) irradiation (Rivas and Ullrich, 1992).
If a relative IL-10 de®ciency is important in the development of
psoriatic in¯ammation, administration of IL-10 might be con-
sidered as a promising therapeutic strategy. We and colleagues have
recently shown that treatment with IL-10 in fact signi®cantly
reduces the clinical activity of psoriasis (Reich et al, 1998; Asadullah
et al, 1999). Initial experiments performed with peripheral blood
mononuclear cells from three patients suggested that a suppression
of APC functions and a shift towards a type 2 cytokine pattern is
involved (Asadullah et al, 1998); however, the effects of IL-10
therapy on the cutaneous immune network have not yet been
investigated. In our study we employed immunohistochemistry,
quantitative real-time reverse transcription±polymerase chain reac-
tion (reverse transcription±PCR), and in situ hybridization to
investigate skin in®ltrating T cell subpopulations, cutaneous
cytokine production, and epidermal pathology in 14 patients
treated with subcutaneous IL-10 over 42 d. Our results show that
the clinical improvement induced by IL-10 is associated with a
downregulation of cutaneous type 1 in¯ammation, suppression of
the epidermal IL-8 pathway, and a normalization of keratinocyte
function. Furthermore, we performed a genetic analysis of
functionally relevant polymorphisms in the TNF-a promoter
region and present some of the ®rst evidence for a possible role of
genetic factors in the response to this new immunotherapeutic
approach.
MATERIALS AND METHODS
Patient characteristics This study was approved by the Institutional
Review Boards of the Medical Faculties in the participating centers.
According to the protocol, patients were included if they had a history of
extensive, long-standing or treatment-resistant, moderate-to-severe, stable
or worsening plaque-type psoriasis (psoriasis vulgaris), were negative for
antibodies to human immunode®ciency virus, hepatitis B and C, and had
no serious concurrent medical problems or a history of cancer. The patients
had no clinical or laboratory evidence for an acute infection, and female
patients were required to have a negative pregnancy test. Previously failed
therapies included topical treatments (n = 15), UVB phototherapy (n = 7),
psoralen UVA (n = 5), cyclosporine A (n = 4), methotrexate (n = 3), or
fumaric acid (n = 2). Thirteen patients were discontinued from (largely
ineffective) topical vitamin D3 analogs, anthraline, or tar preparations 2 wk
before treatment with IL-10. Patients receiving systemic antipsoriatic
regimen, including UVB phototherapy and psoralen UVA, were
discontinued at least 4 wk before entry into the study (n = 7). All
participants gave informed consent before enrolling into the study. Ten
males and ®ve females (mean age 44 y) were treated with IL-10 at the
Departments of Dermatology, Georg-August-University, GoÈttingen, and
Eberhard-Karls-University, TuÈbingen. The mean age of disease onset was
27 y in this group. Thirteen patients had developed psoriasis before the age
of 40 y (early-onset psoriasis).
Study design Within 2 wk before the ®rst injection, medical history was
taken, and the following screening studies were performed: a physical
examination and laboratory testing for hemoglobin, hematocrit,
erythrocyte count, leukocyte and platelet count, blood chemistry panel,
C-reactive protein, ®brinogen, coagulation parameters, antinuclear
antibodies, antibodies to human immunode®ciency virus 1 and 2,
hepatitis C and B, erythrocyte sedimentation rate, and urine analysis,
including a urine pregnancy test in females. In this open pilot trial, eligible
patients received subcutaneous injections of 4 mg per kg body weight of
recombinant human IL-10 (SCH 52000, Schering Plough, Kenilworth,
NJ) once daily into nonlesional skin over a period of 42 d. The clinical
activity of psoriasis was assessed before the ®rst injection (baseline, day 0), at
days 4, 12, 20, 28, and 42 of the treatment period, and every 2 wk during a
6 wk follow-up phase by the psoriasis area and severity index (PASI) and
photographic documentation. Clinical responses at day 42 were classi®ed as
``marked improvement'' (PASI < 50% compared with baseline), ``moderate
improvement'' (PASI > 50, and < 75% compared with baseline), ``stable
disease'' (PASI > 75%, and < 125% compared with baseline), or
``worsening disease'' (PASI > 125% compared with baseline). Marker
plaques of at least 20 cm2 were monitored in each patient by 20 MHz
ultrasound at baseline, day 20 and at the end of therapy (day 42). If the
reduction of the PASI after 3 wk of treatment was < 25% compared with
the baseline values, the dosage of IL-10 was increased from 4 to 8 mg per kg
body weight. During follow-up, patients were treated with emollients until
disease relapse (PASI > 75% of the baseline value) occurred.
Biopsies for routine histology, immunohistochemistry and analysis of
cytokine expression were taken from the active border of representative
chronic plaques (age of the lesions between 6 wk and 3 mo) at baseline, and
24 h after the last injection on day 42. In the ®rst 10 consecutive patients,
biopsies for cytokine analysis and immunohistochemistry were also
obtained 24 h after the third injection on day 3. Patients were physically
examined daily for the ®rst 28 d, and weekly thereafter. Laboratory tests
including blood chemistry, hematology, and urine analysis were repeated
on days 2, 4, 6, 12, 20, 28, 35, and 42 of the treatment period and weeks 2,
4, and 6 of the follow-up. Adverse effects were recorded using common
World Health Organization toxicity criteria.
Histopathology and immunohistochemistry Four millimeter punch
biopsies were prepared for routine histopathology (®xation in 4%
paraformaldehyde) or directly frozen in liquid nitrogen for
immunohistochemical analysis. Immunohistochemistry was performed
employing the avidin-biotin-peroxidase (ABC) technique with 3-amino-
9-ethylcarbazole as the chromogen. Brie¯y, serial sections were air-dried,
®xed in ice-cold 100% acetone for 10 min, preincubated with normal
rabbit serum, followed by incubation with the primary mouse monoclonal
antibody for 1 h at 37°C. A biotin-conjugated rabbit anti-mouse
immunoglobulin antibody (Dako, Hamburg, Germany) was used as
second step reagent, followed by the avidin±biotin±peroxidase complex
(Dako), each incubated at room temperature for 30 min. The reaction time
with the chromogen was 15±20 min. Primary antibodies used in this study
were monoclonal antibody to CD3 (Becton Dickinson, San Jose, CA),
CD4, CD8, Ki-67 (clone MIB1; all purchased from Dako), CD25,
involucrin, CD49c (a3-integrin), cytokeratin-16 (all from Novocastra,
Newcastle, U.K.), transglutaminase K (Biomedical Technologies,
Stoughton, MA), CXCR1 (clone 10H2), and CXCR2 (clone 9H1; both
kindly provided by Dr Chuntharapai, San Francisco, CA). All staining
procedures were also performed on skin biopsies collected from ®ve
healthy volunteers after informed consent had been obtained. In the
negative controls, the primary antibody was substituted by unspeci®c
isotype matched mouse immunoglobulins (Dako). The area and the length
of the epidermis were quantitated on paraf®n sections with an automated
image analysis system (Quantimet, Leica, Nussloch, Germany) and used to
compute mean epidermal thickness. Cells reactive with antibodies to CD3,
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CD4, CD8, and CD25 were counted separately in the epidermis and upper
corium on adjacent cryostat sections using a 0.25 3 0.25 mm ocular grid
(Olympus Optical, Hamburg, Germany) and a 3 400 magni®cation.
Numbers of epidermal T cell subpopulations were determined for the
complete epidermis of each section. In the upper dermis, at least 10
adjacent grid ®elds were analyzed. From the results of duplicate
determinations by two independent investigators, average numbers of
positive cells were calculated for the epidermis (cells per linear mm of
epidermal surface) and the upper dermis (cells per mm2) in each biopsy.
Keratinocytes staining positive for Ki-67 were quantitated similar to
epidermal T cells.
RNA extraction and cDNA synthesis Total RNA was extracted from
30 consecutive 20 mm sections of those skin specimens that were also
analyzed by immunohistochemistry using the RNeasy Mini Kit according
to the manufacturer's protocol (Qiagen, Hilden, Germany). RNA was
eluted in 30 ml RNase-free water (0.1% diethylpyrocarbonate; Sigma,
Deisenhofen, Germany) and the RNA content determined
spectrophotometrically. Following a DNase digestion step (FCLP-pure
DNase I, Pharmacia, Freiburg, Germany), 1 mg of RNA was reverse
transcribed in a total volume of 50 ml RNase-free water including 1.5 mM
pd(T)12±18 (Pharmacia), 0.4 mM of each deoxynucleotide triphosphate
(MBI Fermentas, St Leon-Rot, Germany), and 200 U of reverse
transcriptase (Superscript II; Gibco, Eggenstein, Germany). Synthesis of
cDNA was immediately controlled by PCR for b-actin (see conventional
PCR).
Generation of cytokine standards for quantitative real-time
PCR Two microliters of cDNA were subjected to PCR reactions in a
total reaction volume of 20 ml, containing 2 ml of 10 3 PCR buffer
(including SYBR Green I dye, Taq DNA polymerase, deoxynucleotide
triphosphate; Roche Diagnostics, Mannheim, Germany), 11.25 pmol of
each forward and reverse primer and 4 mM MgCl. PCR consisted of an
initial denaturation step of 30 s at 95°C, followed by 35 (b-actin) or 45
cycles of rapid heating to 95°C, followed by an immediate cooling to the
annealing temperature (b-actin: 66°C, IFN-g: 59°C, IL-8: 55°C, CXCR2:
58°C, TNF-a: 65°C), which was held for 5 s and an elongation step of
(product length [bp]/25) s. Fluorescence was measured at the end of the
elongation step. Reactions without cDNA were always included as a
negative control. Melting curves were generated to obtain melting
temperatures for primer-dimers and the speci®c PCR product (see
below). PCR products were analyzed by agarose gel electrophoresis. The
products were extracted (Pharmacia, Germany) and quantitated. Ten fold
dilution series were prepared in sterile water, ranging from 100 amol per ml
down to 0.0001 amol per ml (corresponding to 60 copies per ml). PCR
product identity was con®rmed by cycle sequencing. The following
oligonucleotide primers were used for real-time reverse transcription±
PCR:
TNF-a: 5¢-GGCTCCAGGCGGTGCTTGTTC-3¢, 5¢-AGACGGCGA-
TGCGGCTGAATG-3¢ (designed according to GenBank locus: HSTNF-
A; product size: 409 bp)
IFN-g: 5¢-GTCGCCAGCAGCTAAAA CAG-3¢, 5¢-CCTAGTTGGCC-
CCTGAGATAAA-3¢ (HUMINTGA; 339 bp)
IL-8: 5¢-GACAAGAGCCAGGAAGAAA-3¢, 5¢-CCAGGAATCTGGT-
ATTGCAT-3¢ (HUMIL8A; 484 bp)
CXCR2: 5¢-AACCCCCTCATCTACGCCTTCATT-3¢, 5¢-TTGGCC-
AGCCTGATTTTCTTTCTT-3¢ (HUMINTLEU8; 509 bp)
b-actin: 5¢-CCCAAGGCCAACCGCGAGAAGAT-3¢, 5¢-GTCCCGG-
CCAGCCAGGTCCAG-3¢ (HSAC07; 219 bp)
Quantitative real-time PCR The LightCycler PCR system (Roche,
Germany; equipped with the LightCycler software version 3.39) allows the
real-time detection of PCR product formation by monitoring the
¯uorescence emitted by SYBR Green I dye intercalating in double
strand PCR products. Quantitation is based on the principle that the
number of original copies of the speci®c cytokine cDNA within the
reaction is inversely proportional to the number of PCR cycles necessary to
generate a signal that rises above background ¯uorescence. By using the
PCR product dilution series as external standards, a calibration curve was
generated that allowed the quantitation of cDNA samples. To exclude
¯uorescence related to the formation of primer-dimers, ¯uorescence was
measured at a cytokine-speci®c temperature, i.e., the temperature (as
obtained from the melting curves) at which primer-dimers had already
completely melted, but at which the speci®c PCR product was not
affected: b-actin, 87°C; IL-8, 80°C; CXCR2, 85°C; IFN-g, 81°C; TNF-
a, 88°C). Hence, during quantitative PCR, the elongation step was
followed by an incubation at the speci®c temperature for 2 s and
¯uorescence detection. Reactions without cDNA were always included
as a negative control, and cDNA samples were quantitated in duplicate.
Variations between duplicate quantitations were typically below 10%.
Values (in amol per ml) obtained for the cytokines of interest were
standardized for b-actin values obtained by the same procedure. For
comparison, quantitation of cytokines was also performed in skin biopsies
from healthy controls (n = 5).
Conventional PCR In biopsies from 10 patients an extended cytokine
spectrum was analyzed by nonquantitative PCR. To determine optimal
conditions cycle titration experiments were performed and PCR run with
the cycle number corresponding to the upper range of linear ampli®cation.
PCR conditions for IL-4 (that was not detected in any of the study samples
or normal skin) were tested with cDNA samples from lesional biopsies of
patients with tumor stage cutaneous T cell lymphoma (n = 3) and active
atopic dermatitis (n = 5). PCR reactions were carried out in a total volume
of 50 ml containing 1 ml cDNA, 1.5 mM MgCl, 0.2 mM deoxynucleotide
triphosphates (MBI Fermentas), 18.75 pmol of each primer, and 1 U Taq
DNA polymerase (Gibco). Each PCR included negative control reactions
without template DNA. PCR products were visualized on agarose gels (1
or 2%) by staining with ethidium bromide. Oligonucleotide primers and
PCR conditions were:
TNF-a: 5¢-AGGCGCTCCCCAAGAAGACAGG-3¢, 5¢-AGGGGAGC-
GTTTGGGAAGGTT-3¢ (product size: 696 bp; 35 cycles; conditions: 45 s
95°C, 45 s 65°C, 90 s 72°C)
IFN-g: 5¢-CTCTCGGAAACGATGAAATA-3¢, 5¢-CCTAGTTGGC-
CCCTGAGATAAA-3¢ (779 bp; 38 cycles; 45 s 95°C, 45 s 48°C, 90 s
72°C)
IL-1b: 5¢-GCGGCATCCAGCTACGAATCTC-3¢, 5¢-GTTATATCC-
TGGCCGCCTTGGGTC-3¢ (GenBank locus: HSIL1BR; 643 bp; 35
cycles; 45 s 95°C, 45 s 58°C, 90 s 72°C)
IL-2: 5¢-TAATCACTACTCACAGTAA-3¢, 5¢-CCAATCTACATAGA-
TACTATA-3¢ (HSIL2R; 744 bp; 38 cycles; 1 min 95°C, 1 min 44°C,
2 min 72°)
IL-4: 5¢-CTGCAAATCGACACCTATTAA-3¢, 5¢-CAGCTCGAACA-
CTTTGAATAT-3¢ (HUMIL4; 481 bp; 35 cycles; 1 min 95°C, 1 min
52°C, 2 min 72°C)
IL-8: primers as above (35 cycles; 45 s 95°C, 45 s 53°C, 90 s 72°C)
CXCR1: 5¢-GTTGCGGATCCTGCCTCACAC-3¢, 5¢-TGTCAGA-
TTCGGGGCTCAGATG-3¢ (HUMIL8RAA; 761 bp; 38 cycles; 45 s
95°C, 45 s 63°C, 90 s 72°C)
CXCR2: 5¢-AGCCTTGGCCGACCTACTCTT-3¢, 5¢-TGGGGGC-
TGCATTGAGACT-3¢ (923 bp; 35 cycles; 1 min 95°C, 1 min 55°C,
2 min 72°C)
IL-10: 5¢-CTGCTCTGTTGCCTGGTCCTCCTG-3¢, 5¢-TCCACGG-
CCTTGCTCTTGTTTTCA-3¢ (HUMIL10; 404 bp; 38 cycles; 45 s 95°C,
45 s 63°C, 90 s 72°C)
IL-10R: 5¢-AGCCCAGCCCCTTCATCTTCAT-3¢, 5¢-TGCAGGG-
CCCCAGTCAACAG-3¢ (K00672; 1159 bp; 35 cycles; 1 min 95°C,
1 min 64°C, 2 min 72°C)
IL-12p40: 5¢-GGATGCCCCTGGAGAAATGGT-3¢, 5¢-CTGGGCCC-
GCACGCTAAT-3¢ (HUMNKSFP40; 817 bp; 35 cycles; 45 s 95°C, 45 s
53°C, 90 s 72°C)
IL-17: 5¢-AACCGGAATACCAATACCAATC-3¢, 5¢-TAGTCCGAAA-
TGAGGCTGTCTT-3¢ (HSU32659; 414 bp; 35 cycles; 45 s 95°C, 45 s
56°C, 90 s 72°C)
b-actin: 5¢-CCCAGCCATGTACGTTGCTAT-3¢, 5¢-GGGTGGCT-
TTTAGGATGGCAA-3¢ (1047 bp; 35 cycles; 45 s 95°C, 45 s 63°C, 90 s
72°C)
In situ hybridization The IL-8 PCR product was cloned into the SmaI
restriction site of the transcription vector pBluescript (pBS, Stratagene,
Heidelberg, Germany). Using this construct as a template, a PCR was
carried out using oligonucleotide primers speci®c for the T3- and T7-
promoter regions of the plasmid. Digoxigenin-11-UTP-labeled sense and
anti-sense probes were generated by in vitro transcription with T3- or T7-
polymerase (Promega, Mannheim, Germany) using 200 ng of the PCR
product as template. The amount of transcript was monitored by agarose
gel electrophoresis and labeling ef®ciency was controlled by dot blot
analysis of serial probe dilutions. In situ hybridization was performed as
described (Breitschopf et al, 1992). Brie¯y, tissue sections were
deparaf®nized and rehydrated in serial dilutions of ethanol. Samples were
permeabilized by Proteinase K (Sigma, 10 mg per ml, 20 min, 37°C). For
blocking endogenous alkaline phosphatase, slides were incubated with
0.25% acetic anhydride (10 min at room temperature) and dehydrated in
serial dilutions of ethanol. Probes (1:50±1:200 according to dot blot results)
were then added, slides were covered and denatured (5 min, 85°C).
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Hybridization was performed overnight at 62°C in a sealed humidi®ed
chamber containing 50% formamide. Afterwards, unbound probe was
removed by RNAse digestion (Boehringer Mannheim, Mannheim,
Germany, 20 mg per ml, 30 min, 37°C) and by the following
posthybridization washes: 1 3 sodium citrate/chloride buffer/0.1%
sodium dodecyl sulfate at room temperature (2 3 5 min) and
0.2 3 sodium citrate/chloride buffer/0.1% sodium dodecyl sulfate at
hybridization temperature (2 3 10 min). Finally, the sections were
washed in Tris-buffered saline (pH 7.4) containing 0.1% Tween-20
(Boehringer). A speci®cally bound probe was detected by an alkaline
phosphatase-conjugated polyclonal sheep anti-digoxigenin antibody F(ab)2
fragment (1:500; Boehringer Mannheim) and NBT/X-phosphate as the
substrate. Specimens were counterstained with hemalaun. Sense probes
were always included as the negative control.
Analysis of TNF-a promoter polymorphisms Lymphocytes were
collected from EDTA blood samples at 400 3 g and 4°C and lyzed in
50 mM trisect pH 8.0, 20 mM EDTA pH 8.0 and 2% sodium dodecyl
sulfate. Protein was digested with Proteinase K (6 h at 56°C) and pelleted
with 6 M NaCl following centrifugation at 5000 3 g for 20 min. DNA was
precipitated with 1.5 3 vol. 100% ethanol. DNA yields were between 0.1
and 1 mg per ml. Polymorphisms at position ±238 of the TNF-a promoter
(G vs A transition at ±238; TNF-238.2 allele) were analyzed by PCR±
restriction fragment length polymorphism as previously described (Day et al,
1998). Allelic variations at position ±308 of the TNF-a promoter (G vs A
transition at ±308; TNF-308.2 allele) were analyzed by allele-speci®c PCR
according to Chouchane et al (1997).
Statistical methods All data groups were tested for Gaussian
distribution. Statistical analysis was by the paired or unpaired t test unless
indicated otherwise. Correlation between variables was analyzed by
Pearson's correlation coef®cient. Variables are described by mean 6 SD
or median and range. Two-tailed p < 0.05 was considered to indicate
statistical signi®cance. Statistical analysis was performed using the prism
2.01 software (GraphPad, San Diego, CA).
RESULTS
Clinical response to IL-10 therapy IL-10 was administered for
42 d to 15 patients with chronic, extensive plaque-type psoriasis.
Clinical data obtained in the ®rst 10 patients have already been
published (Reich et al, 1998). Each of the patients had long-
standing or recalcitrant disease (mean disease duration 17 y). In one
individual, treatment was stopped after 5 wk because of a newly
diagnosed immunogenic hyperthyroidism. In the remaining 14
patients the median PASI score (psoriasis area and severity index), as
a measure of clinical severity, decreased from 22.4 (range 12.4±
53.3) before therapy to 8.4 (3±34) at the end of treatment
(p = 0.0001, Wilcoxon signed rank test). The mean reduction of
the PASI (6 SD) compared with baseline was 31 6 12% (range 12±
50%) at day 12, 50 6 16% (24±74%) at day 28, and 59 6 20% (27±
84%) at day 42 (statistically signi®cant at all points). Therefore, the
most marked clinical improvement occurred within the initial 4 wk
of IL-10 therapy. Clinical effectiveness was also monitored by
sonographic evaluation of marker plaques in each individual. Using
20 MHz ultrasound for quantitation, the echo-poor band
representing acanthosis and in¯ammatory in®ltration of the upper
corium (Hoffmann et al, 1995) decreased from 711 6 244 mm
before to 307 6 297 mm at the end of treatment (p = 0.001).
The clinical response to IL-10 treatment was heterogeneous.
Ten patients showed a marked improvement with a decrease of the
PASI of > 50% (Fig 1a, b), four patients had moderate improve-
ments (PASI decrease < 50%, > 25%; Fig 1c, d). In three of those
four patients the dosage of IL-10 was increased from 4 to 8 mg per
Figure 1. Examples of the clinical response of psoriasis to rhIL-10.
Representative skin lesions before and after 6 wk of treatment in a patient
with marked response (a, b: 84% decrease of the PASI score from 31.8 to
5.2), and in a patient with moderate response (c, d: 49% decrease of the
PASI from 15 to 7.6). Changes in the cutaneous cytokine expression
induced by IL-10 treatment in the former patient are shown in Figs 3 and 5.
Table I. IL-10 therapy reduces the lesional T cell in®ltratea
Baseline after therapy (day 42)
phenotype mean 6 SD (range) mean 6 SD (range) p
EpidermisCD3+ CD3+ 80 6 27 (40±136) 46 6 27 (8±92) < 0.001
(cells per mm surface) CD4+ 41 6 25 (20±124) 22 6 14 (4±48) < 0.05
CD8+ 38 6 18 (12±68) 21 6 15 (0±58) < 0.001
CD25+ 21 6 14 (0±44) 8 6 9 (0±28) < 0.001
Upper corium CD3+ 324 6 133 (155±541) 227 6 131 (84±500) < 0.05
(cells per mm2) CD4+ 207 6 96 (84±428) 133 6 101 (34±386) < 0.05
CD8+ 75 6 48 (9±177) 90 6 54 (28±204) NS
CD25+ 58 6 25 (22±98) 40 6 26 (8±105) < 0.05
aSummay of the effects of IL-10 therapy on lesion-in®ltrating T cell subpopulations as determined by immunohistochemistry in 14 patients. Serial sections of
individual pairs of pre- and post-treatment biopsies obtained from representative marker plaques were stained with antibodies to CD3, CD4, CD8, and CD25 and average
cell numbers were calculated in the epideris (cells per linear mm of epidermal surface) and dermis (cells per mm2 upper corium) as described in Materials and Methods.
Results obtained in pre- and post-treatment groups were compared by the paired t-test. NS, not signi®cant.
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kg after 3 wk according to the protocol, but this did not
signi®cantly improve the clinical response. The baseline activity
of skin lesions (as de®ned by the PASI score and 20 MHz
sonography) was similar in high and low responding patients, and
clinical effects of IL-10 appeared to be independent of disease
duration or the previous response to other treatment modalities.
No serious adverse effects were produced by administration of
IL-10, and the subcutaneous application of the drug was well
accepted by all patients. Mild-to-moderate adverse effects included
headache, gastric pain, exacerbation of pre-existing iritis (one
patient each), and infection of the upper respiratory tract (three
patients). A mild transient reduction of circulating platelets
(maximum individual decrease 28% of baseline value) was typically
observed between day 1 and day 12 of the treatment period.
During the 6 wk follow-up period disease activity remained
controlled in 12 patients without further treatment other than
emollients, whereas in the other two patients a disease relapse
occurred as de®ned by the protocol. Rebound phenomena were
not observed.
IL-10 therapy reduces cutaneous T cell in®ltration and
keratinocyte proliferation The clinical response after 6 wk of
treatment was correlated with changes of T lymphocyte in®ltration
and epidermal activation in biopsy specimens of representative skin
lesions. The effects of IL-10 on cutaneous T cell subpopulations are
summarized in Table I. Mean numbers (6 SD) of intraepidermal T
cells (CD3+ cells per mm epidermal surface) decreased from
80 6 27 before to 46 6 27 at the end of therapy (p < 0.001), and
mean numbers of T cells in®ltrating the upper corium (CD3+ cells
per mm2) decreased from 324 6 133 to 227 6 131 (p < 0.05). Thus,
suppressive effects of IL-10 were more pronounced in the
epidermis (mean reduction 43%) than in the upper corium (mean
reduction 24%). CD4+ and CD8+ subpopulations contributed
about equally to the intraepidermal T cell in®ltrate before therapy
and were both reduced by IL-10 treatment. In the upper corium
CD4+ cells predominated at baseline and were reduced by IL-10
whereas numbers of dermal CD8+ T cells increased under therapy
(Table I). The differential effect of IL-10 on dermal T cell
subpopulations was also re¯ected in a signi®cant decrease of the
CD4/CD8 ratio from 2.5 (median value; range 1.5±15.3) at
baseline to 1.6 (0.6±4.7) after therapy (p = 0.03, Wilcoxon signed
rank test).
Treatment with IL-10 also effectively reduced the number of IL-
2 receptor (CD25) -expressing activated lymphocytes in the
epidermal compartment (mean reduction 71%; p < 0.001) as well
as in the dermal compartment (mean reduction 29%, p < 0.05).
Figure 2 shows the effects of IL-10 on total and activated
epidermal T cells in each of the 14 patients in this study compared
with the individual reductions in epidermal thickness and numbers
of proliferating (Ki-67+) epidermal cells. The four patients with
only moderate clinical improvement (red lines) exhibited the
poorest reduction of cutaneous T cells. In these patients the mean
reduction of intraepidermal T cells was 23% (CD25+ cells 32%)
compared with 52% (CD25+ cells 88%) in the 10 patients with
marked clinical improvements (black lines; Fig 2a, b). Similarly,
statistically signi®cant reductions in epidermal thickness and
Figure 2. Coordinate effects on epidermal T cell in®ltration and
keratinocyte proliferation correlate with the clinical response to
rhIL-10. Quantitative assessment of epidermal T cell in®ltration and
activation (a, b) and epidermal hyperplasia (c, d) in 14 patients before and at
the end of treatment with rhIL-10. Frozen biopsies from pretreatment and
week 6 were stained with antibodies to CD3, CD25, and Ki-67. Numbers
of T cells (CD3+, a), activated T cells (CD25+, b), and proliferating
epidermal cells (Ki-67+, d) are given as cells per mm epidermal surface. In c,
mean epidermal thickness was calculated from surface area/epidermal
length measurements of adjacent biopsies processed for routine histology
made by an image analysis program (each data point corresponds to the
average of triplicate determinations). Results obtained in individual patients
are connected by a line. Mean values in pretreatment and post-treatment
groups (blue horizontal bars) were compared by the paired t test, and p-
values are shown in the upper right of each panel. Patients with marked
clinical response to IL-10 therapy (PASI reduction > 50%) are indicated by
black lines, patients with moderate clinical response (PASI reduction
< 50%, > 25%) are indicated by red lines.
Figure 3. IL-10 therapy downregulates proin¯ammatory type 1 and
IL-8/CXCR2 cytokine pathways. RNA was prepared from pretreat-
ment and post-treatment skin samples of patients with psoriasis (n = 14),
and from biopsies of healthy control subjects (HC; n = 5). Expression levels
of TNF-a, IFN-g, IL-8, and the IL-8 receptor CXCR2 were analyzed by
quantitative real-time reverse transcription±RCR (a, b). Each symbol
corresponds to the average ratio of cytokine to b-actin copies determined
in individual skin samples by duplicate analysis (for details see Materials and
Methods). The data points marked by a frame correspond to the values
obtained in the patient also shown in Figs 1(a, b) and 5. Mean values in
pretreatment and post-treatment groups are indicated by horizontal bars.
Comparison was by the paired t test. *p < 0.05.
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numbers of proliferating epidermal cells were measured for the
entire study population; however, the largest reductions in
these parameters occurred in the patients who showed marked
clinical improvements (Fig 2c, d). It therefore appeared that large
reductions in epidermal thickness and numbers of proliferating
keratinocytes were linked to marked reductions of activated
epidermal T cells. In fact, reduction of these cells was correlated
with improvements in measures of epidermal pathology,
for example, epidermal T cell counts correlated with epidermal
thickness (r = 0.62, p < 0.001) or the number of Ki-67+
epidermal cells (r = 0.6, p < 0.001), and numbers of proliferating
epidermal cells also correlated with the number of epidermal
CD25+ cells (r = 0.64, p < 0.001).
IL-10 therapy downregulates the cutaneous expression of
type 1 cytokines Activated CD4+ and CD8+ T cells represent
an important source of proin¯ammatory mediators in psoriatic
lesions (Szabo et al, 1998). With the ®nding of a reduction of both
subsets after IL-10 treatment, we next investigated the effects of IL-
10 on cutaneous cytokine expression. Using a novel quantitative
real-time reverse transcription±PCR technique we focused on two
aspects of the cytokine network, that have been suggested to play a
central part in disease pathogenesis: the overexpression of type 1
cytokines and the activation of the epidermal IL-8 pathway.
In accordance with published data (Uyemura et al, 1993; Schlaak
et al, 1994), we found an increased lesional expression of type 1
cytokines TNF-a and IFN-g in the majority of patients before
therapy compared with weak or absent expression in biopsies from
healthy control subjects (Fig 3a). Treatment with IL-10 signi®-
cantly downregulated the expression of both cytokines with a mean
reduction of cutaneous IFN-g levels of approximately 55%. Effects
on TNF-a levels were more heterogeneous (80% reduction to 2-
fold increase) and the mean reduction was approximately 20%. The
suppression of cutaneous type 1 cytokines correlated to some extent
Figure 4. IL-10 inhibits the epidermal expression of IL-8 and its receptor, CXCR2. Biopsies were obtained before and after therapy and divided for
immunohistochemistry/quantitative reverse transcription±PCR and in situ hybridization. A strong expression of IL-8 mRNA was detected in basal
(suprapapillary) and suprabasal keratinocytes before treatment by in situ hybridization (b), whereas the surface expression of CXCR2 was mainly restricted to
epidermal cells in the stratum spinosum (e). In accordance with the results of the quantitative reverse transcription±PCR analysis (see Fig 3b), the in situ
mRNA expression of IL-8 and the surface expression of CXCR2 were clearly reduced by IL-10 therapy (c, f). The ®gure gives an example for the almost
complete downregulation observed by in situ hybridization/immunohistochemistry in six of 10 patients with marked clinical response. (a) Sense control (d),
isotype control. Scale bars: (a±c) 200 mm, (d±f) 100 mm.
Figure 5. Early downregulation of cutaneous cytokines (IL-12p40,
IL-17) that promote type 1 and IL-8-dependent in¯ammatory
pathways. Four millimeter punch biopsies for the comparative analysis of
cutaneous cytokine expression before, after 3 d, and at the end of treatment
were available from 10 patients (eight with marked, two with moderate
clinical response). RNA was prepared from 30 consecutive 20 mm sections
and ampli®ed by reverse transcription±PCR. Adjacent sections were
analyzed by immunohistochemistry for T cell in®ltration and keratinocyte
proliferation. The ®gure shows the cytokine expression pattern in a patient
that had a marked clinical response at the end of treatment (see Fig 1a, b).
The result is representative for the early complete downregulation (below
detectable limits) of IL-2 and IL-12p40 observed in seven of eight, and of
IL-17 observed in six of eight patients with marked clinical responses at the
end of treatment. Immunohistochemical parameters at day 3 were
unchanged compared with baseline. For visual comparison, cDNA samples
were prediluted for identical band intensities of b-actin as determined
densitometrically. Note that IL-8 and CXCR2 (in contrast to its inducer
IL-17) are still clearly expressed after 3 d of treatment.
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with the clinical response. For example, none of the patients with
only moderate clinical improvement showed a reduction of
cutaneous IFN-g levels > 50%, whereas half of the patients with
good clinical response had reductions > 80%. In addition, TNF-a
expression was increased in three of four patients with moderate
response, but reduced to < 60% of the baseline values in ®ve of 10
patients with marked response.
From nonquantitatve reverse transcription±PCR analysis, there
was no evidence for the induction of type 2 cytokines or
upregulation of endogenous IL-10 by IL-10 therapy. IL-4 was
detected in three of three skin samples from patients with tumor
stage cutaneous T cell lymphoma and three of ®ve biopsies from
atopic dermatitis lesions; however, IL-4 could not be detected in
any of the pretreatment biopsies and remained undetectable after
therapy. IL-10 and the IL-10 receptor were found to be expressed
in all skin specimens obtained from psoriatic patients at baseline but
not in biopsies from healthy control subjects (n = 5). In ®ve of 14
patients (four with marked, one with moderate clinical response)
treatment with IL-10 resulted in a complete downregulation of
cutaneous IL-10 and in all of these individuals (and one other)
expression of the IL-10 receptor also became undetectable at the
end of therapy (for example, see Fig 5).
IL-10 suppresses the epidermal IL-8/CXCR2 pathway By
quantitative real-time reverse transcription±PCR the response to
IL-10 therapy was also associated with a signi®cant downregulation
of cutaneous levels of IL-8 and its receptor CXCR2 (formerly IL-
8RB), which were overexpressed in all pretreatment specimens
compared with normal skin (Fig 3b). In six individuals expression
levels of IL-8 and CXCR2 were reduced to normal values at the
end of treatment, and all of these patients had marked clinical
improvements. As previously reported (Schmid et al, 1993; Kulke
et al, 1998), epidermal cells constituted a major source of IL-8 in
active lesions and overexpressed CXCR2. By in situ hybridization
strong signals for IL-8 were found in basal and suprabasal epidermal
cells in active psoriasis (Fig 4b), but not in biopsies from healthy
controls. Similarly, immunohistochemistry with antibodies to
CXCR2 failed to demonstrate a signi®cant epidermal expression
of the IL-8 receptor in normal skin, but revealed a membranous
staining pattern of keratinocytes located mainly in the upper
stratum spinosum in psoriasis (Fig 4e), consistent with an increased
surface expression of CXCR2 in lesional epidermis. In accordance
with the quantitative PCR data, the in situ expression of IL-8
mRNA and the surface expression of its receptor were found to be
greatly reduced by IL-10 therapy, especially in patients with
marked clinical response (Fig 4c, f). There was no evidence for a
signi®cant epidermal expression of the CXC receptor type 1
(formerly IL-8RA) or a modulation of CXCR1 levels by IL-10
treatment (data not shown).
Early effects of IL-10 on cutaneous cytokine expression In
10 patients (eight with marked, two with moderate clinical
response), skin samples were also collected after 3 d of treatment
and analyzed for an extended cytokine pro®le including IL-2, IL-
1b, IL-12p40, and IL-17. Results were compared with the
cytokine expression pattern in biopsies obtained from the same
patients before and after treatment. RNA was prepared from 30
consecutive 20 mm sections and ampli®ed by reverse transcription±
PCR. Immunohistochemistry with antibodies to CD3, Ki-67, and
cytokeratin-16 was performed in adjacent sections. IL-1b and IL-
Figure 6. IL-10 reverses the epidermal expression of molecular markers associated with aberrant keratinocyte differentiation. Example of the
effect of rhIL-10 therapy on the expression of selected marker proteins that de®ne keratinocyte hyperproliferation and abnormal differentiation. The
immunohistochemical staining illustrates the almost complete reversal of the psoriatic epidermal phenotype observed in six of 10 patients with marked
clinical response. Pretreatment cryostat sections (a, c, e, g, i, k) are paired with post-treatment sections (b, d, f, h, j, l) of one patient with a marked clinical
response. IL-10 strongly reduced the number of proliferating (Ki-67+) epidermal cells (a, b); in b, positive cells are marked by an arrow. In addition, IL-10
reversed the aberrant expression of cytokeratin-16 (c, d) and a3-integrin (e, f: arrow: focal basal expression after therapy), and normalized the expression of
transglutaminase K (g, h) and its substrate involucrin (i, j). For comparison, the distribution of CD3+ T cells before and after therapy in this patient is also
shown (k, l). Scale bars: (g, h) 50 mm, (k, l) 200 mm; and 100 mm in all other panels.
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12p40 were present in all, and IL-2 in eight of 10 pretreatment
biopsies. Nonquantitative reverse transcription±PCR revealed
strong suppressive effects of IL-10 on the production of
proin¯ammatory cytokines already after 3 d of treatment (Fig 5),
whereas T cell in®ltration and keratinocyte hyperproliferation were
largely unaffected at this early time-point. Notably, in seven of
eight patients with marked clinical response, the expression of IL-2
and IL-12p40 was downregulated to below detectable levels at day
3 and remained absent at the end of therapy (Fig 5).
IL-17, a cytokine released from activated T cells, has recently
been shown to induce the production of IL-8 in keratinocytes
(Teunissen et al, 1998). To investigate whether suppression of IL-
17 might be involved in the downregulation of IL-8 by IL-10
therapy, we compared the early and late effects of IL-10 therapy on
both cytokines. IL-17 was expressed in 10 of 10 psoriatic skin
samples at baseline compared with none of ®ve samples from
healthy control subjects. After three injections of IL-10, expression
of IL-17 was no longer detectable in six of 10 patients (all with
marked clinical response), whereas IL-8 and CXCR2 were clearly
present in all specimens investigated at this time-point (Fig 5). At
the end of treatment, all of those patients with early complete
downregulation of IL-17 had strong reductions of IL-8 levels as
determined by quantitative real-time PCR (for example, compare
Fig 5 with Fig 3b).
IL-10 therapy reverses abnormal epidermal differentiation
On a molecular level, the epidermal changes in psoriasis as related
to hyperproliferation and incomplete and accelerated differentiation
of keratinocytes correspond to alterations in the expression of
speci®c marker proteins. To elucidate the effects of IL-10 therapy
on keratinocyte function further, the expression of several of such
markers, including cytokeratin-16, a3-integrin, transglutaminase
K, and involucrin was studied by immunohistochemistry in all
patients before and after therapy.
Treatment with IL-10 not only reduced epidermal thickness and
keratinocyte proliferation (Fig 2), but had also strong effects on
keratinocyte differentiation. In six of 10 patients with marked
clinical response the epidermal phenotype at the end of treatment
was indistinguishable from the expression pattern found in skin
biopsies from healthy control subjects. Cycling keratinocytes (Ki-
67+) were greatly reduced in number and returned to their normal
localization in the basal layer (Fig 6a, b). Expression of cytokeratin-
16, a subtype of keratin in regenerative epidermis, was almost
completely eliminated (Fig 6c, d), as was the suprabasal expression
of the a3-integrin (CD49c; Fig 6e, f). In addition, the premature
expression of transglutaminase K and its substrate, the corni®ed cell
envelope precursor protein involucrin, was reversed by IL-10
treatment (Fig 6g±j). Finally, hematoxylin and eosin-stained
sections in these patients revealed restoration of the granular layer
and absence of epidermal microabscesses following IL-10 treatment
(not shown). An incomplete reversal of epidermal alterations was
also noted in the other patients. The epidermis thinned,
keratinocyte proliferation decreased (see Fig 2), and there were
moderate effects on markers of keratinocyte differentiation.
TNF-a promoter polymorphisms may in¯uence the
response to IL-10 therapy Recently, polymorphisms have
been detected in the promoter regions of the TNF-a gene that
affect cytokine synthesis. The TNF-238.2 allele (G to A transition
at position ±238) and the TNF-308.2 allele (G to A transition at
position ±308) are associated with increased inducible levels of
TNF-a (Pociot et al, 1995; Wilson et al, 1997). An association
between TNF-a promoter polymorphisms and psoriasis has been
elucidated for the TNF-238.2 allele that is three to four times more
common in patients with early-onset disease compared with
healthy controls (Reich et al, 1999).
To test whether TNF-a promoter polymorphisms may interact
with the response to IL-10 therapy, the TNF-a genotype was
determined in all study patients. PCR/restriction fragment length
polymorphism and allele-speci®c PCR revealed heterozygosity for
TNF-238.2 in four of 14 and heterozygosity for TNF-308.2 in ®ve
of 14 psoriatic patients. Homozygous carriers of variant TNF-a
alleles were not detected. There was no correlation between TNF-
a genotypes and cutaneous TNF-a levels at baseline. Interestingly,
however, all patients with moderate clinical response were carriers
of mutant alleles, whereas all carriers of two wild-type alleles had
marked clinical improvements (Table II). A possible role for TNF-
a promoter polymorphisms in the heterogeneous effects of IL-10
on TNF-a expression was suggested by the ®nding that mean
cutaneous TNF-a mRNA levels were signi®cantly reduced only in
homozygous carriers of the wild-type allele (p < 0.05), but not in
carriers of variant alleles (p = 0.3). The difference in the capacity of
IL-10 to downregulate TNF-a expression in genotypically de®ned
patient subgroups was signi®cant. Mean TNF-a levels (6 SD) at
the end of therapy expressed as percentage of baseline values were
98 6 53% in carriers of variant alleles compared with 41 6 15% in
carriers of two wild-type alleles (p < 0.05; Fig 7).
Figure 7. Reduced capacity of IL-10 to control cutaneous TNF-a
expression in carriers of TNF-a promoter polymorphisms.
Relationship between individual reductions of TNF-a expression levels
in response to IL-10 and the presence of allelic variations in the TNF-a
promoter. TNF-a expression was quantitated by real-time reverse
transcription±PCR in pairs of pretreatment and post-treatment biopsies
from each patient (see also Fig 3a). Values obtained at the end of treatment
are expressed as a percentage of baseline values (set at 100%). Mean values
in each group are shown as horizontal bars. In carriers of variant alleles, i.e.,
patients heterozygous for TNF-238.2 or TNF-308.2 (see Table II), the
mean decrease of TNF-a was < 5% compared with almost 60% in carriers
of two wild-type alleles. *p < 0.05 (t test).
Table II. Carriage of TNFa promoter polymorphisms and
clinical response to IL-10 therapya
TNFa±238 TNFa±308
Moderate n=4 G/G G/G n=0
response G/G G/G n=2
G/G G/G n=2
Marked n=10 G/G G/G n=5
response G/G G/G n=2
G/G G/G n=3
aGenotypic analysis of polymorphims at positions ±238 and ±308 of the TNFa
promoter in patients treated with IL-10. Allelic variations were investigated by
PCR/RFLP (TNF±238.2 allele: A at ±238) or allele-speci®c PCR (TNF±308.2
allele: A at ±308). Individuals homozygous for the wild-type allele (G at both
positions) were detected in half of patients wtih marked clinical response (PASI
reduction > 50%). All patients with moderate clinical response (PASI reduction
< 50%, > 25%) were carriers of variant alleles..
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DISCUSSION
Since its ®rst description in 1989 (Fiorentino et al, 1989) important
immunoregulatory activities of IL-10 have been identi®ed such as
inhibition of accessory cell functions of monocytes/macrophages
and dendritic cells, suppression of proin¯ammatory cytokine and
chemokine production, and prevention of antigen-speci®c T cell
responses (reviewed by De Vries, 1995). These unique anti-
in¯ammatory properties suggest a potential therapeutic role in
autoimmune and in¯ammatory diseases. Until now ef®cacy of IL-
10 treatment has in fact been documented in various animal disease
models in which Th1-cell-mediated immunity and overexpression
of cytokines are likely to play an important part, including
endotoxin- or superantigen-induced sepsis (Gerard et al, 1993;
Florquin et al, 1994), collagen-induced chronic arthritis (Walmsley
et al, 1996), and different forms of experimental colitis (reviewed in
Leach et al, 1999). In contrast, only limited data are available on the
effectiveness of IL-10 therapy in human disease. Systemic
administration of recombinant human (rh) IL-10 appeared
bene®cial in patients with Crohn's disease (Van Deventer et al,
1997), and was shown to suppress the production of proin¯amma-
tory cytokines in healthy volunteers challenged with endotoxin
(Pajkrt et al, 1997) or transplant recipients receiving anti-CD3
antibodies (Wissing et al, 1997).
In this open pilot study we extend our previous ®ndings on the
ef®cacy of subcutaneous IL-10 in psoriasis (Reich et al, 1998), a
common chronic skin in¯ammation driven by type 1 cells. The
mean reduction of the clinical activity after 6 wk of treatment was
60%, comparable with the results obtained in another open pilot
trial with 10 patients (Asadullah et al, 1999). More important, we
show that the clinical response to IL-10 therapy is associated with
effects on major established pathogenic aspects of the disease. IL-10
reduced cutaneous T cell in®ltration and activation, downregulated
the proin¯ammatory type 1 and IL-8/CXCR2 cytokine pathways,
and at least partially reversed abnormal keratinocyte proliferation
and differentiation. These data indicate that IL-10 plays a central
part in psoriasis that is based on the negative modulation of the
psoriatic in¯ammatory cascade at multiple levels.
In vitro studies have shown that IL-10 suppresses T cell functions
mainly through inhibition of accessory activities of APC. Admin-
istration of a single i.v. bolus of IL-10 to healthy volunteers
inhibited the production of proin¯ammatory monokines TNF-a
and IL-1b in whole blood stimulated ex vivo with endotoxin
(Chernoff et al, 1995). Reduced monocytic expression of HLA-DR
and endotoxin-induced secretion of TNF-a and IL-12 was also
reported in an earlier trial with three psoriatic patients (Asadullah
et al, 1998). Therefore, reductions of cutaneous T cell in®ltration
and type 1 cytokine expression observed in this study may
predominantly re¯ect suppressive effects of IL-10 on cutaneous
macrophages and dendritic cells. In a considerable number of
patients, IL-10 in fact induced a complete early (after 3 d of
treatment) downregulation of IL-12, that plays a key part in the
differentiation of activated T cells towards type 1 cells. The effect of
IL-10 on the expression of IL-12p40 is of particular interest because
IL-12p40 is selectively upregulated in psoriasis, whereas IL-12p35 is
expressed at similar levels in normal and psoriatic skin (Yawalkar
et al, 1998). Other possible effects of IL-10 in the control of APC
function may include the downregulation of costimulatory
molecules such as CD86 that are overexpressed on lesional
dendritic cells and participate in the preferential induction of type
1 responses (Mitra et al, 1995).
Suppression of T cell activation was re¯ected by the down-
regulation of cutaneous IL-2 synthesis and the signi®cant decrease
of T cells expressing the IL-2 receptor (CD25). Among in®ltrating
lymphocytes the latter subset of activated T cells is likely to play a
crucial part in disease pathogenesis as suggested by the clinical
response of psoriasis to DAB389IL-2, a fusion protein that
selectively inhibits CD25+ cells (Gottlieb et al, 1995). Accordingly,
these cells (approximately 20% of total epidermal and dermal T cells
before therapy in this study) may represent an essential source of
proin¯ammatory cytokines in psoriatic lesions. Comparison of
serial sections revealed activated T cells among CD4+ as well as
CD8+ lymphocytes and both subpopulations have been identi®ed
as sources of type 1 cytokines in psoriasis (Szabo et al, 1998). In
contrast to in®ltrating CD4+ cells that were reduced in the dermis
and epidermis, reductions of intraepidermal CD8+ cells, however,
were accompanied by increased dermal CD8 counts at the end of
therapy. It may therefore be speculated that treatment with IL-10
induced a cutaneous redistribution rather than a true epidermal
clearing of CD8+ T cells. Such an effect could be related to the
CD8-selective chemoattractive properties of IL-10 and the
differential capacity to inhibit chemotaxis of CD4+ and CD8+
cells in response to other factors, such as IL-8 (Jinquan et al, 1993).
Our ®ndings on the suppression of T cell activation and cutaneous
IL-12p40 production substantiate the clinical observation that IL-
10 treatment decreases cutaneous delayed-type hypersensitivity
responses to recall antigens (Asadullah et al, 1999).
Ef®cacy of IL-10 in psoriasis may at least partly be explained by
the exogenous substitution of a relative IL-10 de®ciency (Nickoloff
et al, 1994; Asadullah et al, 1998). The induction of endogenous IL-
10 by IL-10 therapy was reported in three patients treated with
subcutaneous IL-10 (8 mg per kg body wt) over 24 d (Asadullah et al,
1998); hypothetically, this induction may contribute to a prolonged
reversal of psoriatic pathogenic pathways. In our study, however,
IL-10 therapy induced a complete downregulation of endogenous
IL-10 and its receptor in ®ve of 14 patients (four of them with
marked clinical response). In addition, from the analysis of
cutaneous IL-4 levels, there was no evidence for a shift towards a
type 2 cytokine pattern in the skin as might have been expected
from observations that circulating IgE levels and proportions of
IL-4 producing peripheral T cells were increased in response to
IL-10 treatment (Asadullah et al, 1998).
Disease improvements induced by IL-10 therapy were correlated
with strong effects on the series of epidermal alterations that de®ne
psoriasis. Thus, acanthosis, hyperproliferation, parakeratosis, ab-
normal differentiation and neutrophilic in®ltration were all at least
partially reversed by IL-10 treatment. Another characteristic aspect
of epidermal pathology in psoriasis is that keratinocytes themselves
become activated to function as in¯ammatory effector cells and
produce cytokines that perpetuate the in¯ammatory process. An
important example is the induction of the epidermal IL-8 pathway
characterized by a keratinocytic overexpression of IL-8 and its
receptor CXCR2 in psoriatic lesions (Schmid et al, 1993; Kulke
et al, 1998). Paracrine activities of keratinocyte-derived IL-8 are
mainly related to its chemoattractive properties. These are thought
to contribute to the epidermal accumulation of T cells and
neutrophils in lesional skin. Autocrine effects include the stimula-
tion of epidermal cell growth (Tuschil et al, 1992) and
proin¯ammatory activities such as the induction of major
histocompatibility complex class II expression (Kemeny et al,
1995) and the upregulation of the inducible nitric oxide synthase
(Bruch-Gerharz et al, 1996). In our study we showed that IL-10
therapy, similar to the systemic administration of FK506 (Lemster
et al, 1995), strongly reduces the epidermal expression of IL-8 and
CXCR2 as documented by immunohistochemistry, in situ
hybridization, and quantitative real-time reverse transcription±
PCR.
Keratinocytes have recently been shown to express IL-10
receptors and IL-10 was found to prevent cytokine-induced
keratinocyte activation in vitro (Michel et al, 1997). Therefore,
alternative hypotheses for the striking effect of IL-10 therapy on
epidermal cell functions are that IL-10 indirectly affects keratino-
cytes through inhibition of cytokine production in in®ltrating T
cells or that IL-10 antagonizes epidermal activation by direct
activities on keratinocytes. In line with the former concept, a
downregulation of proin¯ammatory cytokine expression by IL-10
was already detectable after 3 d of treatment when epidermal
alterations (as determined by histologic criteria and expression of
Ki-67) were still largely unchanged. Also, improvements in
epidermal thickness and keratinocyte proliferation in response to
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IL-10 therapy correlated with reductions in activated intraepider-
mal T cells (Fig 2), indicating that suppression of these cells
represents a crucial step in the normalization of keratinocyte
function by IL-10.
The effects of IL-10 on cutaneous cytokine expression and
psoriatic epidermal pathology display striking similarities with those
of experimental IL-11 therapy in that both cytokines appear to
ameliorate psoriasis mainly through the preferential inhibition of
cutaneous type 1 in¯ammatory pathways (Trepicchio et al, 1999).
One possible explanation is that both cytokines inhibit the nuclear
factor-kB-dependent transcriptional activation of type 1 cytokine
genes (Trepicchio et al, 1997; Schottelius et al, 1999). Complete
clinical clearing, observed in a substantial proportion of patients
receiving cyclosporine A (Ellis et al, 1991), was not achieved in any
of the patients in our study nor among the 12 patients treated with
IL-11. Consistent with the incomplete clinical response to IL-10
therapy, post-treatment mRNA levels of proin¯ammatory cyto-
kines TNF-a, IFN-g, and IL-8, although greatly reduced,
remained above those detected in skin biopsies from healthy
volunteers in the majority of patients. This raises the possibility that
the doses of IL-10 used in our initial study (4±8 mg per kg) were not
high enough and/or that the length of the treatment period was
insuf®cient. The dose selection was based on the results of a clinical
trial with doses between 0.5 and 25 mg per kg in patients with
Crohn's disease, where it was found that intermediate doses similar
to those given in our study produced the best clinical effects,
whereas higher doses were associated with more side-effects
without signi®cantly improving ef®cacy (Van Deventer et al, 1997).
We observed large interindividual variations in the clinical
response to IL-10; the mean PASI decrease in the four patients with
the highest clearing rates was 84 6 1% compared with 37 6 14% in
the four patients with the lowest clearing rates. This heterogeneity
parallels differences in the improvements produced by other
immunomodulatory agents, including IL-11 (Trepicchio et al,
1999), and may be explained by the existence of disease subgroups
within psoriasis. A stronger in¯uence of genetic factors and a more
severe disease course has been postulated for patients with juvenile
onset compared with those with late onset psoriasis (Henseler and
Christophers, 1985). Relevance of this concept to the subclassi®ca-
tion of psoriasis has recently been con®rmed by the ®nding that
early-onset but not late-onset disease is associated with a
polymorphism at position ±238 of the TNF-a promoter (Reich
et al, 1999). Thus, the relatively high frequency of carriers of the
TNF-238.2 allele in our study population (four of 14) may result
from the high proportion of participants with early-onset disease
(13 of 14). Increased production of TNF-a has been demonstrated
in peripheral lymphocytes of carriers of TNF-a promoter
polymorphisms after stimulation in vitro (Pociot et al, 1995; Wilson
et al, 1997), but the relation to cytokine production in vivo is not
known. In this study, the expression levels of TNF-a in psoriatic
lesions before treatment were similar in patients carrying variant
TNF alleles and those carrying two wild-type alleles; however, it
appeared that the capacity of IL-10 to suppress cutaneous TNF-a
production was signi®cantly lower in carriers of variant TNF
alleles. Moreover, all four patients with only moderate clinical
response were carriers of variant alleles compared with ®ve of 10
patients with marked clinical response (and none of the four
patients with the highest clearing rates). We therefore speculate that
(i) promoter polymorphisms confer a partial resistance towards the
control of TNF-a production by IL-10 (that may result from
altered binding af®nities of regulatory elements to the TNF-a
gene), and that (ii) the heterogeneity in the clinical response to IL-
10 treatment is at least partially based on genetically determined
differences within psoriatic patients.
In summary, the data presented in this study may further the
understanding of the immunoregulatory functions of IL-10 in
psoriasis and other diseases characterized by the activation of type 1
cytokine pathways. Although a number of issues need to be
addressed in future studies such as the selection of dosage and
treatment time, the duration of remission, and the possible
induction of IL-10 antibodies, our results strongly support the
concept that the administration of IL-10 is a promising therapeutic
approach in psoriasis. Finally, we present some of the ®rst evidence
that the analysis of genotypic factors may help to de®ne subgroups
within this common disorder, which will preferentially respond to
IL-10 therapy.
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